Busse, C
2196  Ergebnisse:
Personensuche X
?
1

P115 Ustekinumab in DEVELOP: A safety analysis from an Infl..:

Koletzko, S ; Veereman, G ; Hyams, J...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i402-i403 , 2024
 
?
3

P436 Efficacy and safety of intravenous ustekinumab re-indu..:

Schreiber, S W ; Lee, S ; van der Woude, C J...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i564-i566 , 2023
 
?
 
?
 
?
8

Criteria evaluation for the transition of cracking modes in..:

Busse, C. ; Gustafsson, D. ; Palmert, F....
Theoretical and Applied Fracture Mechanics.  106 (2020)  - p. 102453 , 2020
 
?
9

Integration digitaler Technologien für das Engineering, den..:

Busse, C. ; Pfeiffer, B. M. ; Roth, M....
Chemie Ingenieur Technik.  92 (2020)  9 - p. 1250-1250 , 2020
 
?
11

P446 Dose escalation with originator infliximab is more com..:

Escher, J ; Dubinsky, M ; Izanec, J...
Journal of Crohn's and Colitis.  13 (2019)  Supplement_1 - p. S334-S335 , 2019
 
?
12

P347 New-onset autoimmune disorders, primarily psoriasis, i..:

Veereman, G ; Griffiths, A ; Colletti, R...
Journal of Crohn's and Colitis.  13 (2019)  Supplement_1 - p. S276-S277 , 2019
 
?
13

P651 Disease severity and intensity of therapy predicts ser..:

Winter, H ; Izanec, J ; Busse, C..
Journal of Crohn's and Colitis.  13 (2019)  Supplement_1 - p. S445-S445 , 2019
 
?
14

Evaluation of the crystallographic fatigue crack growth rat..:

Busse, C. ; Palmert, F. ; Sjödin, B....
International Journal of Fatigue.  127 (2019)  - p. 259-267 , 2019
 
1-15